Loading
SRMS (Tyrosine-protein kinase Srms) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
Non-receptor tyrosine-protein kinase which phosphorylates DOK1 on tyrosine residues. Also phosphorylates KHDRBS1/SAM68 and VIM on tyrosine residues. Phosphorylation of KHDRBS1 is EGF-dependent.
Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.40, genetic association 0.00, clinical 0.96).
In plain words · SRMS (Tyrosine-protein kinase Srms) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
SRMS (Tyrosine-protein kinase Srms) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
Non-receptor tyrosine-protein kinase which phosphorylates DOK1 on tyrosine residues. Also phosphorylates KHDRBS1/SAM68 and VIM on tyrosine residues.
No product in this corpus aims at SRMS yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SRMS: RNA tissue enhanced (epididymis 2 nTPM, lymphoid tissue 2 nTPM, stomach 1 2 nTPM); no normal tissue stained high; highest cancer staining head and neck cancer (2 of 3 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (chronic myeloid leukemia, acute lymphoblastic leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SRMS tissue; Open Targets ENSG00000125508 associations
First described 2001. Earliest sequence paper UniProt cites for the protein: Deloukas et al, Nature, 2001, "The DNA sequence and comparative analysis of human chromosome 20". Source.
Sources: HGNC HGNC:11298 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9H3Y6 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000125508 (association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.54, non-Hodgkin lymphoma 0.55, chronic myelogenous leukaemia, BCR-ABL1 positive 0.58, myeloproliferative neoplasm 0.58, leukaemia 0.59 (GraphQL API, CC0))
Non-receptor tyrosine-protein kinase which phosphorylates DOK1 on tyrosine residues. Also phosphorylates KHDRBS1/SAM68 and VIM on tyrosine residues. Phosphorylation of KHDRBS1 is EGF-dependent. Phosphorylates OTUB1, promoting deubiquitination of RPTOR. Location: Cytoplasm (UniProt). Locus 20q13.33 (HGNC).
RNA: tissue enhanced (epididymis 2 nTPM, lymphoid tissue 2 nTPM, stomach 1 2 nTPM), detected in some normal tissues.
No normal tissue stained high.
Medium only: glioma, lung cancer, skin cancer, thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SRMS" OR ABSTRACT:"SRMS" OR TITLE:"src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites" OR ABSTRACT:"src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites" OR TITLE:"Tyrosine-protein kinase Srms" OR ABSTRACT:"Tyrosine-protein kinase Srms" OR TITLE:"dJ697K14.1" OR ABSTRACT:"dJ697K14.1" OR TITLE:"PTK70" OR ABSTRACT:"PTK70" OR TITLE:"C20orf148" OR ABSTRACT:"C20orf148") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRMS, not a curated reading list.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.